New combination therapy safe, promising for melanoma patients

Jun 01, 2008

The combination of two different biotherapies may be beneficial for patients with inoperable melanoma, according to a University of Pittsburgh Cancer Institute (UPCI) study presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

Researchers in the melanoma and skin cancer program at UPCI combined two biotherapies – treatments that stimulate the immune system to fight cancer – and found the results promising in terms of anti-tumor effects and tolerable in terms of toxicity. High-dose interferon alfa-2b, a standard treatment for metastatic skin cancer, and tremelimumab, an antibody thought to instigate the body’s immune system to attack tumors, were combined for the first time in this phase 2 clinical trial.

“With each new study, we learn something important about melanoma,” said John M. Kirkwood, M.D., leader of the program and professor and vice chairman for clinical research in the Department of Medicine, University of Pittsburgh School of Medicine. “With this study, we learned that adding tremelimumab to traditional treatment is not only safe, but an effective way to induce an anti-tumor response, which is very exciting.”

For this study, 16 patients diagnosed with stage 4 melanoma, all of whom received and had not benefited from at least one round of previous therapy, were given the combination treatment. The overall response rate was 19 percent, and the study has since moved into the second stage, where it will enroll 21 additional patients.

Melanoma is a rare form of skin cancer, but it causes the majority of skin cancer-related deaths. Each year, approximately 160,000 new cases are diagnosed worldwide, and currently surgery is the only effective cure. For patients with inoperable disease, like those enrolled in this study, discovering a safe and effective treatment is vital.

Source: University of Pittsburgh

Explore further: Prosocial internet support group not beneficial for breast cancer

add to favorites email to friend print save as pdf

Related Stories

Senators get no clear answers on air bag safety

3 hours ago

There were apologies and long-winded explanations, but after nearly four hours of testimony about exploding Takata air bags, senators never got a clear answer to the question most people have: whether or ...

Nicaragua: Studies say canal impact to be minimal

3 hours ago

Officials said Thursday that studies have determined a $40 billion inter-oceanic canal across Nicaragua will have minimal impact on the environment and society, and construction is to begin next month.

Former Brown dean whose group won Nobel Prize dies

3 hours ago

David Greer, a doctor who co-founded a group that won the 1985 Nobel Peace Prize for working to prevent nuclear war and who helped transform the medical school at Brown University, has died. He was 89.

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

Nov 21, 2014

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

Nov 21, 2014

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

E_L_Earnhardt
not rated yet Jun 01, 2008
Nearly all "cancers" result from accelerated mitosis, which involves ENERGY, (ie high-speed electrons). "Freezing" kills any cell, (robbing it of energy). "Cooling", (decreasing electron speed & energy), slows mitosis, arrests cancer!

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.